Today: 30 April 2026
Palantir stock slips in premarket as Karp’s college alternative grabs attention
29 December 2025
2 mins read

Palantir stock slips in premarket as Karp’s college alternative grabs attention

NEW YORK, December 29, 2025, 06:45 ET — Premarket

  • Palantir shares were down about 0.9% in premarket trading, after falling 2.8% at Friday’s close.
  • A report detailed CEO Alex Karp’s new paid “Meritocracy Fellowship” aimed at high school graduates as an alternative to college.
  • Investors head into a holiday-shortened final week with Fed minutes and housing data on deck.

Palantir Technologies shares fell $1.76, or 0.9%, to $186.95 in U.S. premarket trading on Monday. The data-analytics company ended Friday at $188.71.

The move matters because Palantir has been one of 2025’s biggest winners, with its share price up about 150% for the year, leaving the stock more sensitive to shifts in risk appetite in the final sessions of the year.

It also puts a spotlight on valuation. Palantir is trading at roughly 437 times trailing earnings — the stock price relative to the company’s past 12 months of profit — according to StockAnalysis.com, a level that can amplify swings when sentiment turns.

Investors were also digesting a report on CEO Alex Karp’s latest push to challenge conventional credentials. Investopedia said Palantir paid 22 high school graduates about $5,400 a month this fall to forgo college and join a four-month training program with the potential for full-time engineering roles.

“American universities are broken,” Karp said, according to Investopedia. The report said Palantir has not confirmed how many fellows will ultimately receive job offers. Investopedia

Investopedia said Palantir is accepting applications for its next fellowship in New York City, running from August to December 2026.

Palantir’s dip came as U.S. stock index futures edged lower to start the holiday-shortened week, with tech and AI-linked names such as Nvidia and Oracle also down in premarket trading, a Reuters report said.

For Palantir, the next catalyst is still earnings and whether growth holds up against lofty expectations. Wall Street Horizon’s earnings calendar lists Feb. 2, 2026 as an “unconfirmed” after-market report date, meaning the company has not announced it and the date is forecast from past patterns. Wall Street Horizon

Analysts tracked by StockAnalysis.com have an average rating of “Hold,” with a 12-month price target of $171.74 — below the stock’s recent trading level. StockAnalysis.com

Macro data may shape the tape before the opening bell. The National Association of Realtors is due to release pending home sales for November at 10 a.m. ET on Monday, a report that can move rate expectations and, by extension, high-multiple growth stocks.

Investors are also watching minutes from the Federal Reserve’s December meeting on Tuesday and weekly jobless claims on Wednesday, Investopedia said in a weekly markets preview.

As background, Palantir’s stock has been supported this year by enthusiasm around demand for its AI-powered analytics software, especially from U.S. commercial customers and government agencies. In November, the company forecast fourth-quarter revenue above Wall Street estimates and raised its full-year outlook, Reuters reported.

Traders are watching whether the shares can stabilize after last week’s slide. StockAnalysis.com shows a 52-week trading range of $63.40 to $207.52, leaving the stock near the upper end of its yearly band even after the recent pullback.

Stock Market Today

  • Biogen Shares Rise 6% After Q1 Earnings Beat Despite Guidance Cut
    April 29, 2026, 9:29 PM EDT. Biogen (NASDAQ: BIIB) shares rose 6% on Wednesday following its first-quarter 2026 earnings report. The biotech posted $2.48 billion in revenue, surpassing analyst expectations of $2.25 billion. Net income, excluding accounting standards (GAAP), increased 19% to over $529 million, or $3.57 per share, above forecasts of $2.95. Growth was driven by strong sales of Leqembi, for early Alzheimer's, up 74%, and the FDA-approved Skyclarys for Friedreich's ataxia. However, Biogen cut full-year adjusted net income guidance by $1 per share citing research and development charges. Revenue is expected to decline mid-single digits from 2025, excluding a pending $5.6 billion acquisition of Apellis Pharmaceuticals. Biogen's strategic shift towards high-potential therapies is underway despite cautious outlook.

Latest article

Soluna Holdings Stock Jumps After Sazmining Bitcoin Deal, Then SEC Resale Filing Lands

Soluna Holdings Stock Jumps After Sazmining Bitcoin Deal, Then SEC Resale Filing Lands

30 April 2026
Soluna Holdings filed to register the resale of about 2.46 million common shares, with no proceeds going to the company. The move follows Sazmining’s launch of a 3-megawatt Bitcoin mining operation at Soluna’s Project Dorothy 1B in West Texas. Soluna shares last traded at $1.28, up from a $1.08 Nasdaq sale price on April 28. The registered shares include 2.4 million issuable to YA II PN, LTD. via warrant exercise.
Brookfield Renewable Stock Drops 12% Before Q1 Results as BEPC Investors Brace for Friday

Brookfield Renewable Stock Drops 12% Before Q1 Results as BEPC Investors Brace for Friday

30 April 2026
Brookfield Renewable Corp’s NYSE shares fell 12.5% to $35.20 on Wednesday, with volume quadrupling the three-month average ahead of first-quarter results due Friday. The drop came despite a higher quarterly dividend and mixed analyst views. The company operates 47 GW of clean energy assets globally. Analysts expect a first-quarter loss of 33.92 cents per share on $1.62 billion in revenue.
Copper spikes near $13,000 a ton as London catches up after holiday, tariff fears bite
Previous Story

Copper spikes near $13,000 a ton as London catches up after holiday, tariff fears bite

AI cheating crackdown: ACCA moves exams back to test centres, ends most remote sittings
Next Story

AI cheating crackdown: ACCA moves exams back to test centres, ends most remote sittings

Go toTop